<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01593488</url>
  </required_header>
  <id_info>
    <org_study_id>CILI</org_study_id>
    <secondary_id>2011-002622-48</secondary_id>
    <nct_id>NCT01593488</nct_id>
  </id_info>
  <brief_title>Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children</brief_title>
  <acronym>CILI</acronym>
  <official_title>Multicentered Phase II Study Evaluating the Activity and Toxicity of Liposomal Cytarabine in the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia With Resistent or Relapsed Central Nervous System Involvement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Santobono-Pausilpon Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bologna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe the activity and toxicity of a new formulation of
      cytarabine called liposomal cytarabine given into the central nervous system for the
      treatment of central nervous system localization of acute lymphoblastic leukemia (ALL) in
      children and adolescents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liposomal cytarabine (DepoCyte) is a new formulation of the drug cytarabine, a drug commonly
      used in the treatment of ALL. This formulation of the drug can be given intrathecally (into
      the spinal fluid), and is released slowly over a longer period, about two weeks. This allows
      a longer exposure of the drug to the central nervous system, and requires fewer intrathecal
      injections for the patient.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of cerebrospinal fluid (CSF) responses</measure>
    <time_frame>from two weeks after date of patient registration until the date of second consecutive cerebrospinal fluid exam that is negative for malignant cells, up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of patients with grade 3 or higher neurological adverse events, excluding headache) according to CTCAE 4.02</measure>
    <time_frame>assessed from date of patient registration to date of cerebrospinal fluid response, up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to reaching CSF response</measure>
    <time_frame>date of patient registration to date of CSF response, up to 12 weeks</time_frame>
    <description>date of reaching CSF response is the first date of two consecutive negative cytomorphologic exams of CSF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of CSF response</measure>
    <time_frame>up to 12 months</time_frame>
    <description>duration of response is the length of time in days from the date of the CSF response to the date of the first positive cytomorphologic CSF exam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>worst grade non neurologic Adverse event during induction, according to CTCAE 4.02</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>worst grade toxicity after induction therapy according to CTCAE 4.02</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Measured from date of CSF response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time from patient registration to progression of disease in non CNS site</measure>
    <time_frame>up to one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of study drug present in CSF at each induction therapy</measure>
    <time_frame>prior to each induction therapy at 15 day intervals for up to 6 cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation of activity and toxicity with residual study drug level in CSF during induction</measure>
    <time_frame>measured at 15 day intervals for up to 6 cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Intrathecal liposomal cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal cytarabine</intervention_name>
    <description>given intrathecally in induction phase every 15 days until CSF response for up to 7 injections. Then it is given every 4 weeks during consolidation phase while patient awaiting bone marrow transplant. For those patients who are not candidates for a bone marrow transplant, the drug will be given every 3 months for 4 administrations (maintenance therapy)</description>
    <arm_group_label>Intrathecal liposomal cytarabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &lt; 18 years

          -  Diagnosis of acute lymphoblastic leukemia (ALL)

          -  Central nervous system involvement with malignant cells present in cerebrospinal fluid

          -  CNS involvement may be refractive to prior systemic therapy, a first recurrence after
             prior systemic and intrathecal therapy or a second recurrence

          -  CNS involvement may be an isolated lesion or present with other sites of disease

          -  ECOG performance status 0-2

          -  Life expectancy of at least 8 weeks

          -  Absence of severe organ dysfunction

          -  Informed consent

        Exclusion Criteria:

          -  Eligibility for AIEOP studies of first recurrence of ALL,and receiving therapy in a
             center participating in the AIEOP studies

          -  Concurrent treatment with experimental therapies

          -  Severe neurologic toxicities from previous chemotherapy

          -  Severe coagulopathy at time of recurrence

          -  Sepsis

          -  Intrathecal therapy within 1 week of planned study therapy

          -  Total body or head and spine radiation within 8 weeks of enrolment

          -  Bone marrow transplant within 8 weeks of start of study therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosanna Parasole, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Santobono - Pausilipon Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massimo Di Maio, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A. Pession</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico S. Orsola-Malpighi, Bologna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Morello</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico S. Orsola-Malpighi, Bologna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>E. Strocchi</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bologna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Massimo Di Maio, M.D.</last_name>
    <phone>+39 081 5903383</phone>
    <email>massimo.dimaio@usc-intnapoli.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rosanna Parasole, MD</last_name>
    <phone>+39 081 5903571</phone>
    <email>gianfranco.defeo@usc-intnapoli.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>P.O. Gaspare Rodolico</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto G. Gasilini</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Gerardo Clinica Pediatrica</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AORN Santobon - Pauslipon</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Universit√† Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ARNAS Osp Civico di Cristina</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Bambino Gesu'</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Burlo Garofalo Istituto per l'Infanzia Emato Oncologia</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2012</study_first_submitted>
  <study_first_submitted_qc>May 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2012</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent</keyword>
  <keyword>CNS disease</keyword>
  <keyword>intrathecal therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

